Delivery Order SPE2DB24D8003-SPE2DB25FJTZH

Award Date 3/13/25
Potential Completion Date 3/14/25
Potential Value $2.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA), a defense agency, to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, with a ceiling value of $1,035.87, is for the delivery of MOUNJARO 10 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract is a firm fixed-price delivery order with a period of performance through February 6, 2025. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $1,041.10, is for the delivery of MOUNJARO 10 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, with a performance period through January 2, 2024. Dakota Drug, Inc. holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA as part of the DLA Troop Support Medical's ECAT...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of the pharmaceutical product MOUNJARO 2.5 MG/0.5 ML PEN 0.5ML. The fixed-price contract has a ceiling value of $6,350.45 and a period of performance through March 10, 2025. Dakota Drug, Inc. is an established federal contractor, holding a large Indefinite Delivery Contract (IDC) with the DLA worth up to $999,999,999.00 to provide a wide range...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of MOUNJARO 2.5 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $2,377.68 and a performance period through April 7, 2025. It is a Firm Fixed Price contract and is not set-aside. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, providing a wide range of pharmaceutical products, medical supplies, and...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of Mounjaro 7.5 mg/0.5 ml pens. The contract has a ceiling value of $1,958.20 and a period of performance through October 28, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Dakota Drug, Inc. and the DLA Troop Support Medical division, valued at $999,999,999.00, to provide a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of MOUNJARO 10 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $2,172.90 and a period of performance through October 18, 2024. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, valued at $999,999,999.00, which allows the company to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of MOUNJARO 10 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, with a ceiling value of $1,188.84 and a period of performance through January 24, 2025. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a wide range of pharmaceutical products, medical supplies, and...
This federal contract award, valued at $2,694.90, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract is a delivery order for the pharmaceutical product MOUNJARO 12.5 MG/0.5 ML PEN 0.5ML. The contract has an ultimate completion date of August 30, 2024 and is structured as a firm fixed-price agreement. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC)...
The Defense Logistics Agency (DLA) awarded a $1,828.50 firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of 4565765799 - MOUNJARO 10 MG/0.5 ML PEN 0.5ML. This contract award, identified as SPE2DB24FJTMQ, has an ultimate completion date of September 9, 2024. Dakota Drug, Inc. is a for-profit subchapter S corporation that specializes in providing pharmaceutical products, medical supplies, and healthcare equipment to the...
This federal contract award, issued by the Defense Logistics Agency (DLA), is for the delivery of MOUNJARO 10 MG/0.5 ML PEN 0.5ML pharmaceutical products. The award, valued at $2,006.80, was made to Dakota Drug, Inc., a self-certified small disadvantaged business, on February 21, 2025, with a completion date of February 24, 2025. The contract is a Firm Fixed Price Delivery Order, and is not associated with a set-aside program. Dakota Drug, Inc. is a key supplier of pharmaceutical and medical...
  • SPE2DB24D8003
    Indefinite Delivery Contract
  • SPE2DB24D8003-SPE2DB25FJTZH
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $2,511.38, is for the delivery of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract has a firm fixed price pricing type and a completion date of March 14, 2025.

Dakota Drug, Inc. is also the holder of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, which is part of the DLA Troop Support Medical's ECAT Generation V Program. This IDC allows the company to provide a comprehensive range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations.

The contract awarded in this case does not have a set-aside designation, indicating that it was competed on an unrestricted basis.

Generated 6/12/25, 10:09 AM